Allogeneic hematopoietic cell transplantation in patients with CML chronic phase in the era of third generation tyrosine kinase inhibitors: a retrospective study by the Chronic Malignancies Working Party of the EBMT

Following the introduction of tyrosine kinase inhibitors (TKI), the number of patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) for chronic phase (CP) chronic myeloid leukemia (CML) has dramatically decreased. Imatinib was the first TKI introduced to the clinical arena, pr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of hematology 2022-10, Vol.98, p.112-121
Hauptverfasser: Chalandon, Y., Sbianchi, G., Gras, L., Koster, L., Apperley, J., Byrne, J., Salmenniemi, U., Sengeloev, H., Aljurf, M., Helbig, G., Kinsella, F., Choi, G., Reményi, P., Snowden, J. A., Robin, Marie, Lenhoff, S., Mielke, S., Passweg, J., Broers, A. E. C., Kröger, N., Yegin, Z. A., Tan, S. M., Hayden, P. J., Mclornan, D. P., Yakoub-Agha, Ibrahim
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 121
container_issue
container_start_page 112
container_title American journal of hematology
container_volume 98
creator Chalandon, Y.
Sbianchi, G.
Gras, L.
Koster, L.
Apperley, J.
Byrne, J.
Salmenniemi, U.
Sengeloev, H.
Aljurf, M.
Helbig, G.
Kinsella, F.
Choi, G.
Reményi, P.
Snowden, J. A.
Robin, Marie
Lenhoff, S.
Mielke, S.
Passweg, J.
Broers, A. E. C.
Kröger, N.
Yegin, Z. A.
Tan, S. M.
Hayden, P. J.
Mclornan, D. P.
Yakoub-Agha, Ibrahim
description Following the introduction of tyrosine kinase inhibitors (TKI), the number of patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) for chronic phase (CP) chronic myeloid leukemia (CML) has dramatically decreased. Imatinib was the first TKI introduced to the clinical arena, predominantly utilized in the first line setting. In cases of insufficient response, resistance, or intolerance, CML patients can subsequently be treated with either a second or third generation TKI. Between 2006 and 2016, we analyzed the impact of the use of 1, 2, or 3 TKI prior to allo-HCT for CP CML in 904 patients. A total of 323-, 371-, and 210 patients had 1, 2, or 3 TKI prior to transplant, respectively; imatinib (n = 778), dasatinib (n = 508), nilotinib (n = 353), bosutinib (n = 12), and ponatinib (n = 44). The majority had imatinib as first TKI (n = 747, 96%). Transplants were performed in CP1, n = 549, CP2, n = 306, and CP3, n = 49. With a median follow-up of 52 months, 5-year OS for the entire population was 64.4% (95% CI 60.9–67.9%), PFS 50% (95% CI 46.3–53.7%), RI 28.7% (95% CI 25.4–32.0%), and NRM 21.3% (95% CI 18.3–24.2%). No difference in OS, PFS, RI, or NRM was evident related to the number of TKI prior to allo-HCT or to the type of TKI (p = ns). Significant factors influencing OS and PFS were > CP1 versus CP1 and Karnofsky performance (KPS) score > 80 versus ≤80, highlighting CP1 patients undergoing allo-HCT have improved survival compared to >CP1 and the importance of careful allo-HCT candidate selection.
doi_str_mv 10.1002/ajh.26764
format Article
fullrecord <record><control><sourceid>hal</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04516118v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>oai_HAL_hal_04516118v1</sourcerecordid><originalsourceid>FETCH-hal_primary_oai_HAL_hal_04516118v13</originalsourceid><addsrcrecordid>eNqVjc1OQjEQhRujEfxZ-AazdQG2FyjgDgnGBSQuSFzeDJeBDpb2pq2Y-6S-jkV4AVdz5syZ7wjxoGRXSVk84c50Cz3U_QvRVnKsOyM9KC5FW_a0ylqOW-Imxp2USvVH8lq0errQWsthW_xMrPVbcsQVGNpj8rVnSnmryFpIAV2sLbqEib0DdlBnRS5F-OZkYLqYQ2WCd_mjNhjpGEmGgAKC32TJYQ3HgnAipCb4yI7gk90pbnjFyYf4DAiBUj7XVCU-EMT0tW5g1fwBp-eWBVreOnQVU4QPHzJnC-8YUnPqI5i9LJZ34mqDNtL9ed6Kx9fZcvrWMWjLOvAeQ1N65PJtMi-PnuwPlFZqdFC9_2R_AdBzfDk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Allogeneic hematopoietic cell transplantation in patients with CML chronic phase in the era of third generation tyrosine kinase inhibitors: a retrospective study by the Chronic Malignancies Working Party of the EBMT</title><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><creator>Chalandon, Y. ; Sbianchi, G. ; Gras, L. ; Koster, L. ; Apperley, J. ; Byrne, J. ; Salmenniemi, U. ; Sengeloev, H. ; Aljurf, M. ; Helbig, G. ; Kinsella, F. ; Choi, G. ; Reményi, P. ; Snowden, J. A. ; Robin, Marie ; Lenhoff, S. ; Mielke, S. ; Passweg, J. ; Broers, A. E. C. ; Kröger, N. ; Yegin, Z. A. ; Tan, S. M. ; Hayden, P. J. ; Mclornan, D. P. ; Yakoub-Agha, Ibrahim</creator><creatorcontrib>Chalandon, Y. ; Sbianchi, G. ; Gras, L. ; Koster, L. ; Apperley, J. ; Byrne, J. ; Salmenniemi, U. ; Sengeloev, H. ; Aljurf, M. ; Helbig, G. ; Kinsella, F. ; Choi, G. ; Reményi, P. ; Snowden, J. A. ; Robin, Marie ; Lenhoff, S. ; Mielke, S. ; Passweg, J. ; Broers, A. E. C. ; Kröger, N. ; Yegin, Z. A. ; Tan, S. M. ; Hayden, P. J. ; Mclornan, D. P. ; Yakoub-Agha, Ibrahim</creatorcontrib><description>Following the introduction of tyrosine kinase inhibitors (TKI), the number of patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) for chronic phase (CP) chronic myeloid leukemia (CML) has dramatically decreased. Imatinib was the first TKI introduced to the clinical arena, predominantly utilized in the first line setting. In cases of insufficient response, resistance, or intolerance, CML patients can subsequently be treated with either a second or third generation TKI. Between 2006 and 2016, we analyzed the impact of the use of 1, 2, or 3 TKI prior to allo-HCT for CP CML in 904 patients. A total of 323-, 371-, and 210 patients had 1, 2, or 3 TKI prior to transplant, respectively; imatinib (n = 778), dasatinib (n = 508), nilotinib (n = 353), bosutinib (n = 12), and ponatinib (n = 44). The majority had imatinib as first TKI (n = 747, 96%). Transplants were performed in CP1, n = 549, CP2, n = 306, and CP3, n = 49. With a median follow-up of 52 months, 5-year OS for the entire population was 64.4% (95% CI 60.9–67.9%), PFS 50% (95% CI 46.3–53.7%), RI 28.7% (95% CI 25.4–32.0%), and NRM 21.3% (95% CI 18.3–24.2%). No difference in OS, PFS, RI, or NRM was evident related to the number of TKI prior to allo-HCT or to the type of TKI (p = ns). Significant factors influencing OS and PFS were &gt; CP1 versus CP1 and Karnofsky performance (KPS) score &gt; 80 versus ≤80, highlighting CP1 patients undergoing allo-HCT have improved survival compared to &gt;CP1 and the importance of careful allo-HCT candidate selection.</description><identifier>ISSN: 0361-8609</identifier><identifier>EISSN: 1096-8652</identifier><identifier>DOI: 10.1002/ajh.26764</identifier><identifier>PMID: 36266607</identifier><language>eng</language><publisher>Wiley</publisher><subject>Life Sciences</subject><ispartof>American journal of hematology, 2022-10, Vol.98, p.112-121</ispartof><rights>Attribution - NoDerivatives</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://hal.univ-lille.fr/hal-04516118$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Chalandon, Y.</creatorcontrib><creatorcontrib>Sbianchi, G.</creatorcontrib><creatorcontrib>Gras, L.</creatorcontrib><creatorcontrib>Koster, L.</creatorcontrib><creatorcontrib>Apperley, J.</creatorcontrib><creatorcontrib>Byrne, J.</creatorcontrib><creatorcontrib>Salmenniemi, U.</creatorcontrib><creatorcontrib>Sengeloev, H.</creatorcontrib><creatorcontrib>Aljurf, M.</creatorcontrib><creatorcontrib>Helbig, G.</creatorcontrib><creatorcontrib>Kinsella, F.</creatorcontrib><creatorcontrib>Choi, G.</creatorcontrib><creatorcontrib>Reményi, P.</creatorcontrib><creatorcontrib>Snowden, J. A.</creatorcontrib><creatorcontrib>Robin, Marie</creatorcontrib><creatorcontrib>Lenhoff, S.</creatorcontrib><creatorcontrib>Mielke, S.</creatorcontrib><creatorcontrib>Passweg, J.</creatorcontrib><creatorcontrib>Broers, A. E. C.</creatorcontrib><creatorcontrib>Kröger, N.</creatorcontrib><creatorcontrib>Yegin, Z. A.</creatorcontrib><creatorcontrib>Tan, S. M.</creatorcontrib><creatorcontrib>Hayden, P. J.</creatorcontrib><creatorcontrib>Mclornan, D. P.</creatorcontrib><creatorcontrib>Yakoub-Agha, Ibrahim</creatorcontrib><title>Allogeneic hematopoietic cell transplantation in patients with CML chronic phase in the era of third generation tyrosine kinase inhibitors: a retrospective study by the Chronic Malignancies Working Party of the EBMT</title><title>American journal of hematology</title><description>Following the introduction of tyrosine kinase inhibitors (TKI), the number of patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) for chronic phase (CP) chronic myeloid leukemia (CML) has dramatically decreased. Imatinib was the first TKI introduced to the clinical arena, predominantly utilized in the first line setting. In cases of insufficient response, resistance, or intolerance, CML patients can subsequently be treated with either a second or third generation TKI. Between 2006 and 2016, we analyzed the impact of the use of 1, 2, or 3 TKI prior to allo-HCT for CP CML in 904 patients. A total of 323-, 371-, and 210 patients had 1, 2, or 3 TKI prior to transplant, respectively; imatinib (n = 778), dasatinib (n = 508), nilotinib (n = 353), bosutinib (n = 12), and ponatinib (n = 44). The majority had imatinib as first TKI (n = 747, 96%). Transplants were performed in CP1, n = 549, CP2, n = 306, and CP3, n = 49. With a median follow-up of 52 months, 5-year OS for the entire population was 64.4% (95% CI 60.9–67.9%), PFS 50% (95% CI 46.3–53.7%), RI 28.7% (95% CI 25.4–32.0%), and NRM 21.3% (95% CI 18.3–24.2%). No difference in OS, PFS, RI, or NRM was evident related to the number of TKI prior to allo-HCT or to the type of TKI (p = ns). Significant factors influencing OS and PFS were &gt; CP1 versus CP1 and Karnofsky performance (KPS) score &gt; 80 versus ≤80, highlighting CP1 patients undergoing allo-HCT have improved survival compared to &gt;CP1 and the importance of careful allo-HCT candidate selection.</description><subject>Life Sciences</subject><issn>0361-8609</issn><issn>1096-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqVjc1OQjEQhRujEfxZ-AazdQG2FyjgDgnGBSQuSFzeDJeBDpb2pq2Y-6S-jkV4AVdz5syZ7wjxoGRXSVk84c50Cz3U_QvRVnKsOyM9KC5FW_a0ylqOW-Imxp2USvVH8lq0errQWsthW_xMrPVbcsQVGNpj8rVnSnmryFpIAV2sLbqEib0DdlBnRS5F-OZkYLqYQ2WCd_mjNhjpGEmGgAKC32TJYQ3HgnAipCb4yI7gk90pbnjFyYf4DAiBUj7XVCU-EMT0tW5g1fwBp-eWBVreOnQVU4QPHzJnC-8YUnPqI5i9LJZ34mqDNtL9ed6Kx9fZcvrWMWjLOvAeQ1N65PJtMi-PnuwPlFZqdFC9_2R_AdBzfDk</recordid><startdate>20221023</startdate><enddate>20221023</enddate><creator>Chalandon, Y.</creator><creator>Sbianchi, G.</creator><creator>Gras, L.</creator><creator>Koster, L.</creator><creator>Apperley, J.</creator><creator>Byrne, J.</creator><creator>Salmenniemi, U.</creator><creator>Sengeloev, H.</creator><creator>Aljurf, M.</creator><creator>Helbig, G.</creator><creator>Kinsella, F.</creator><creator>Choi, G.</creator><creator>Reményi, P.</creator><creator>Snowden, J. A.</creator><creator>Robin, Marie</creator><creator>Lenhoff, S.</creator><creator>Mielke, S.</creator><creator>Passweg, J.</creator><creator>Broers, A. E. C.</creator><creator>Kröger, N.</creator><creator>Yegin, Z. A.</creator><creator>Tan, S. M.</creator><creator>Hayden, P. J.</creator><creator>Mclornan, D. P.</creator><creator>Yakoub-Agha, Ibrahim</creator><general>Wiley</general><scope>1XC</scope><scope>VOOES</scope></search><sort><creationdate>20221023</creationdate><title>Allogeneic hematopoietic cell transplantation in patients with CML chronic phase in the era of third generation tyrosine kinase inhibitors: a retrospective study by the Chronic Malignancies Working Party of the EBMT</title><author>Chalandon, Y. ; Sbianchi, G. ; Gras, L. ; Koster, L. ; Apperley, J. ; Byrne, J. ; Salmenniemi, U. ; Sengeloev, H. ; Aljurf, M. ; Helbig, G. ; Kinsella, F. ; Choi, G. ; Reményi, P. ; Snowden, J. A. ; Robin, Marie ; Lenhoff, S. ; Mielke, S. ; Passweg, J. ; Broers, A. E. C. ; Kröger, N. ; Yegin, Z. A. ; Tan, S. M. ; Hayden, P. J. ; Mclornan, D. P. ; Yakoub-Agha, Ibrahim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-hal_primary_oai_HAL_hal_04516118v13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Life Sciences</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chalandon, Y.</creatorcontrib><creatorcontrib>Sbianchi, G.</creatorcontrib><creatorcontrib>Gras, L.</creatorcontrib><creatorcontrib>Koster, L.</creatorcontrib><creatorcontrib>Apperley, J.</creatorcontrib><creatorcontrib>Byrne, J.</creatorcontrib><creatorcontrib>Salmenniemi, U.</creatorcontrib><creatorcontrib>Sengeloev, H.</creatorcontrib><creatorcontrib>Aljurf, M.</creatorcontrib><creatorcontrib>Helbig, G.</creatorcontrib><creatorcontrib>Kinsella, F.</creatorcontrib><creatorcontrib>Choi, G.</creatorcontrib><creatorcontrib>Reményi, P.</creatorcontrib><creatorcontrib>Snowden, J. A.</creatorcontrib><creatorcontrib>Robin, Marie</creatorcontrib><creatorcontrib>Lenhoff, S.</creatorcontrib><creatorcontrib>Mielke, S.</creatorcontrib><creatorcontrib>Passweg, J.</creatorcontrib><creatorcontrib>Broers, A. E. C.</creatorcontrib><creatorcontrib>Kröger, N.</creatorcontrib><creatorcontrib>Yegin, Z. A.</creatorcontrib><creatorcontrib>Tan, S. M.</creatorcontrib><creatorcontrib>Hayden, P. J.</creatorcontrib><creatorcontrib>Mclornan, D. P.</creatorcontrib><creatorcontrib>Yakoub-Agha, Ibrahim</creatorcontrib><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>American journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chalandon, Y.</au><au>Sbianchi, G.</au><au>Gras, L.</au><au>Koster, L.</au><au>Apperley, J.</au><au>Byrne, J.</au><au>Salmenniemi, U.</au><au>Sengeloev, H.</au><au>Aljurf, M.</au><au>Helbig, G.</au><au>Kinsella, F.</au><au>Choi, G.</au><au>Reményi, P.</au><au>Snowden, J. A.</au><au>Robin, Marie</au><au>Lenhoff, S.</au><au>Mielke, S.</au><au>Passweg, J.</au><au>Broers, A. E. C.</au><au>Kröger, N.</au><au>Yegin, Z. A.</au><au>Tan, S. M.</au><au>Hayden, P. J.</au><au>Mclornan, D. P.</au><au>Yakoub-Agha, Ibrahim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Allogeneic hematopoietic cell transplantation in patients with CML chronic phase in the era of third generation tyrosine kinase inhibitors: a retrospective study by the Chronic Malignancies Working Party of the EBMT</atitle><jtitle>American journal of hematology</jtitle><date>2022-10-23</date><risdate>2022</risdate><volume>98</volume><spage>112</spage><epage>121</epage><pages>112-121</pages><issn>0361-8609</issn><eissn>1096-8652</eissn><abstract>Following the introduction of tyrosine kinase inhibitors (TKI), the number of patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) for chronic phase (CP) chronic myeloid leukemia (CML) has dramatically decreased. Imatinib was the first TKI introduced to the clinical arena, predominantly utilized in the first line setting. In cases of insufficient response, resistance, or intolerance, CML patients can subsequently be treated with either a second or third generation TKI. Between 2006 and 2016, we analyzed the impact of the use of 1, 2, or 3 TKI prior to allo-HCT for CP CML in 904 patients. A total of 323-, 371-, and 210 patients had 1, 2, or 3 TKI prior to transplant, respectively; imatinib (n = 778), dasatinib (n = 508), nilotinib (n = 353), bosutinib (n = 12), and ponatinib (n = 44). The majority had imatinib as first TKI (n = 747, 96%). Transplants were performed in CP1, n = 549, CP2, n = 306, and CP3, n = 49. With a median follow-up of 52 months, 5-year OS for the entire population was 64.4% (95% CI 60.9–67.9%), PFS 50% (95% CI 46.3–53.7%), RI 28.7% (95% CI 25.4–32.0%), and NRM 21.3% (95% CI 18.3–24.2%). No difference in OS, PFS, RI, or NRM was evident related to the number of TKI prior to allo-HCT or to the type of TKI (p = ns). Significant factors influencing OS and PFS were &gt; CP1 versus CP1 and Karnofsky performance (KPS) score &gt; 80 versus ≤80, highlighting CP1 patients undergoing allo-HCT have improved survival compared to &gt;CP1 and the importance of careful allo-HCT candidate selection.</abstract><pub>Wiley</pub><pmid>36266607</pmid><doi>10.1002/ajh.26764</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0361-8609
ispartof American journal of hematology, 2022-10, Vol.98, p.112-121
issn 0361-8609
1096-8652
language eng
recordid cdi_hal_primary_oai_HAL_hal_04516118v1
source Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection)
subjects Life Sciences
title Allogeneic hematopoietic cell transplantation in patients with CML chronic phase in the era of third generation tyrosine kinase inhibitors: a retrospective study by the Chronic Malignancies Working Party of the EBMT
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T18%3A54%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-hal&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Allogeneic%20hematopoietic%20cell%20transplantation%20in%20patients%20with%20CML%20chronic%20phase%20in%20the%20era%20of%20third%20generation%20tyrosine%20kinase%20inhibitors:%20a%20retrospective%20study%20by%20the%20Chronic%20Malignancies%20Working%20Party%20of%20the%20EBMT&rft.jtitle=American%20journal%20of%20hematology&rft.au=Chalandon,%20Y.&rft.date=2022-10-23&rft.volume=98&rft.spage=112&rft.epage=121&rft.pages=112-121&rft.issn=0361-8609&rft.eissn=1096-8652&rft_id=info:doi/10.1002/ajh.26764&rft_dat=%3Chal%3Eoai_HAL_hal_04516118v1%3C/hal%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/36266607&rfr_iscdi=true